REMD-477

Phase 2Small molecule

RREMD Biotherapeutics, Inc.

REMD-477 is one of 134 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

133

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

HyperglycemiaActive, not recruiting

Breast CancerActive, not recruiting

Type 1 DiabetesActive, not recruiting

Type 1 Diabetes MellitusActive, not recruiting

Type 2 Diabetes MellitusPhase 1/Phase 2

Active, not recruiting

HyperglycemiaPhase 1

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Type 1 DiabetesPhase 1/Phase 2

Active, not recruiting

Type 1 Diabetes MellitusPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tykerb

GSK

Preclinical

80 2

Trodelvy

Gilead

Preclinical

37 3

REMD-477

RREMD Biotherapeutics, Inc.

Phase 2

1 4

Avastin

Prolia

14 6

Gemzar

GGynecologic Oncology Group

Preclinical

22 7

Megace

Bristol-Myers Squibb

Preclinical

4 8

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 9

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 10

Naltrexone/bupropion

Novo Nordisk

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 1 Diabetes2 trials

Metabolic Pathways of GRA in Patients With Type 1 Diabetes

Completed·UUniversity of California, San Diego·Phase 1/2·NCT03919617·4 enrolled

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

Completed·UUniversity of California, San Diego·Phase 1/2·NCT04545411·12 enrolled

Type 1 Diabetes Mellitus2 trials

Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

Completed·RREMD Biotherapeutics, Inc.·Phase 2·NCT03117998·154 enrolled

Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

Completed·RREMD Biotherapeutics, Inc.·Phase 1·NCT02715193·21 enrolled

Hyperglycemia1 trial

A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib

Terminated·—·Phase 1·NCT04253223·1 enrolled

Metabolism1 trial

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT05093517·4 enrolled

Type 2 Diabetes Mellitus1 trial

Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus

Completed·RREMD Biotherapeutics, Inc.·Phase 1/2·NCT02455011·75 enrolled

2 more indications

Breast Cancer1 trial

Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

Terminated·—·Phase 1·NCT04330625·1 enrolled

Unspecified1 trial

Effects of GRA in Patients With Type 1

Active, not recruiting·UUniversity of California, San Diego·Phase 2·NCT04779645·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for REMD-477. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REMD-477 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REMD-477. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — REMD Biotherapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RREMD Biotherapeutics, Inc.

REMD-477

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 1 Diabetes2 trials

Type 1 Diabetes Mellitus2 trials

Hyperglycemia1 trial

Metabolism1 trial

Type 2 Diabetes Mellitus1 trial

Breast Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News